Action NORDICUS Partners (QB) - NORD

NORDICUS Partners Corporation (QB) (NORD) Action

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

2,45

( -27,77% )

Prix Achat

0,30

Prix Vente

4,04

Volume échangé

1 214

Volume moyen (3 m)

US$ 2 665

Volume financier

US$ 3 238

2,44 Fourchette du Jour 3,14

1,48 Plage de 52 semaines 5,95

Cap du marché

46,976M

Valeur d'Entreprise

46,767M

Clôture Veille

3,392

Ouverture

3,14

Dernière Transaction

100

2.45

Dernière heure de transaction

VWAP

2,6671

Chiffre d'affairess (LTM)

Bénéfice net (LTM)

-4,55M

Actions en circulation

19 173 742

Flottant (%)

16,44%

Détention Institutionnelle (%)

Rendement du Dividende (LTM)

Ratio Cours sur Bénéfices

-9,54

Ratio Cours/Ventes (P/S)

Bénéfice par action (BPA)

-0,26

Bêta

-0,74

Nordicus Partners Corporation operates as publicly traded business accelerator and holding company for Nordic life sciences companies in the United States. The company focused on developing medicines supporting oral health. It also provides corporate finance activities, including business and market... Nordicus Partners Corporation operates as publicly traded business accelerator and holding company for Nordic life sciences companies in the United States. The company focused on developing medicines supporting oral health. It also provides corporate finance activities, including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. The company was formerly known as EKIMAS Corporation and changed its name to Nordicus Partners Corporation in May 2023. Nordicus Partners Corporation was founded in 1993 and is based in Beverly Hills, California. Show more

Secteur

Financials

Industrie

Capital Markets

Site Web

nordicuspartners.com

Siège social

Beverly Hills, United States

Fondé

1993

NORDICUS Partners Corporation (QB) est coté dans le secteur Financials de la OTC Markets avec le ticker NORD. Le dernier cours de clôture d'NORDICUS Partners (QB) était de US$3,39. Au cours de la dernière année, les actions de NORDICUS Partners (QB) ont été négociées dans une fourchette de prix de US$ 1,48 à US$ 5,95.

NORDICUS Partners (QB) compte actuellement 19 173 742 actions en circulation. La capitalisation boursière d'NORDICUS Partners (QB) est de US$46,98 million. NORDICUS Partners (QB) a un ratio cours/bénéfice (ratio PE) de -9.54.

Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405

Form 8-K - Current report

Nordicus Partners Corporation Corporate Update

Orocidin's QR-01 demonstrates efficacy in two preclinical periodontitis models; micro-CT confirms reduced bone...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nordicus Partners Corporation Corporate Update

BEVERLY HILLS, California, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

NoviThera has initiated the first efficacy animal studies

BEVERLY HILLS, California, Nov. 13, 2025 (GLOBE NEWSWIRE) -- NoviThera ApS (“NoviThera”), a majority owned...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.293	-10.6817353263	2.743	3.392	2.44	1062	3.1146903	CS
4	-1.08022	-30.5992261106	3.53022	3.75	1.48	1619	2.45124675	CS
12	-1.57	-39.0547263682	4.02	4.1	1.48	2352	3.56248204	CS
26	-2.4305	-49.8002253867	4.8805	4.8805	1.48	2989	3.71402277	CS
52	0.55	28.9473684211	1.9	5.95	1.48	2225	3.94843169	CS
156	1.7	226.666666667	0.75	10.16	0.45	1852	3.33943788	CS
260	1.4	133.333333333	1.05	10.16	0.45	1880	3.16535273	CS

NORD - Frequently Asked Questions (FAQ)

What is the current NORDICUS Partners Corporation (QB) share price?

The current share price of NORDICUS Partners Corporation (QB) is US$ 2,45

How many NORDICUS Partners Corporation (QB) shares are in issue?

NORDICUS Partners Corporation (QB) has 19 173 742 shares in issue

What is the market cap of NORDICUS Partners Corporation (QB)?

The market capitalisation of NORDICUS Partners Corporation (QB) is USD 46,98M

What is the 1 year trading range for NORDICUS Partners Corporation (QB) share price?

NORDICUS Partners Corporation (QB) has traded in the range of US$ 1,48 to US$ 5,95 during the past year

What is the PE ratio of NORDICUS Partners Corporation (QB)?

The price to earnings ratio of NORDICUS Partners Corporation (QB) is -9,54

What is the registered address of NORDICUS Partners Corporation (QB)?

The registered address for NORDICUS Partners Corporation (QB) is 280 South Beverly Dr, Beverly Hills, California, 90212

What is the NORDICUS Partners Corporation (QB) website address?

The website address for NORDICUS Partners Corporation (QB) is nordicuspartners.com

Which industry sector does NORDICUS Partners Corporation (QB) operate in?

NORDICUS Partners Corporation (QB) operates in the Capital Markets sector

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

NORDICUS Partners Corporation (QB) (NORD)

NORDICUS Partners Corporation (QB) (NORD) Action

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de NORDICUS Partners Corporation (QB)

NORD Dernières nouvelles

Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405

Form 8-K - Current report

Nordicus Partners Corporation Corporate Update

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nordicus Partners Corporation Corporate Update

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

NoviThera has initiated the first efficacy animal studies

Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405

Form 8-K - Current report

Nordicus Partners Corporation Corporate Update

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nordicus Partners Corporation Corporate Update

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

NoviThera has initiated the first efficacy animal studies

Form 4 - Statement of changes in beneficial ownership of securities

Orocidin’s QR-01 Shows Positive Results in Treating Periodontitis in the treatment of experimental periodontitis in Wistar rats.

NORD - Frequently Asked Questions (FAQ)

NORD Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités